Benefitting From Expanded Access in Europe, Roche’s Ocrevus is on Track to Displace Biogen’s Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
EXTON, Pa., Oct. 7, 2019 /PRNewswire/ -- Expanded access to Merck KGaA's Mavenclad and Roche's Ocrevus in Europe has significantly...